These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24440085)

  • 1. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
    Tolcher A; Goldman J; Patnaik A; Papadopoulos KP; Westwood P; Kelly CS; Bumgardner W; Sams L; Geeganage S; Wang T; Capen AR; Huang J; Joseph S; Miller J; Benhadji KA; Brail LH; Rosen LS
    Eur J Cancer; 2014 Mar; 50(5):867-75. PubMed ID: 24440085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
    Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
    Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
    Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.
    Leohr JK; Luffer-Atlas D; Luo MJ; DeBrota DJ; Green C; Mabry TE; Suico JG
    J Clin Pharmacol; 2018 Apr; 58(4):412-424. PubMed ID: 29178617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
    Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
    Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
    Azaro A; Rodon J; Calles A; Braña I; Hidalgo M; Lopez-Casas PP; Munoz M; Westwood P; Miller J; Moser BA; Ohnmacht U; Bumgardner W; Benhadji KA; Calvo E
    Invest New Drugs; 2015 Jun; 33(3):710-9. PubMed ID: 25902900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
    J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
    Cohen RB; Aamdal S; Nyakas M; Cavallin M; Green D; Learoyd M; Smith I; Kurzrock R
    Eur J Cancer; 2013 May; 49(7):1521-9. PubMed ID: 23433846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
    Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
    Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
    Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
    Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
    Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
    Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
    Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
    Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.
    Rodon J; Postel-Vinay S; Hollebecque A; Nuciforo P; Azaro A; Cattan V; Marfai L; Sudey I; Brendel K; Delmas A; Malasse S; Soria JC
    Eur J Cancer; 2017 Aug; 81():142-150. PubMed ID: 28624695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
    Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
    Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
    Varga A; Soria JC; Hollebecque A; LoRusso P; Bendell J; Huang SA; Wagle MC; Okrah K; Liu L; Murray E; Sanabria-Bohorquez SM; Tagen M; Dokainish H; Mueller L; Burris H
    Clin Cancer Res; 2020 Mar; 26(6):1229-1236. PubMed ID: 31848189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
    Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.